[PDF] Top 20 Therapy to target renal cell carcinoma using 131 I-labeled B7-H3 monoclonal antibody
Has 10000 "Therapy to target renal cell carcinoma using 131 I-labeled B7-H3 monoclonal antibody" found on our website. Below are the top 20 most common "Therapy to target renal cell carcinoma using 131 I-labeled B7-H3 monoclonal antibody".
Therapy to target renal cell carcinoma using 131 I-labeled B7-H3 monoclonal antibody
... Renal cell carcinoma (RCC) is the most common malignant tumor in the adult kidney, accounting for ...and renal pelvis cancer in 2015 ... See full document
11
Expression and significance of B7-H3 and Tie-2 in the tumor vasculature of clear cell renal carcinoma
... angiogenesis. B7-H3, a new member of the B7 family of costimula- tory molecules, has a critical function in the T-cell-mediated antitumor immune response, and abnormal tumor ... See full document
8
<p>Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+ regulatory T cells in renal cell carcinoma</p>
... the B7 family of immunoregula- tory proteins, which includes PD-L1 (also known as B7-H1), and is thought to control tumor aggressiveness in various types of cancer, including ...11–16,25–27 ... See full document
10
Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
... the target lesions of all patients after the first cycle of ...the target lesions decreased from 14% to 5%, although large differences were observed between ... See full document
7
Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy
... prostate, renal, pancreatic, thyroid, glioblastoma, astrocy- toma, colorectal and bladder cancers ...disrupted cell–cell and cell–matrix contacts ...of cell migration and the ex- ... See full document
14
Potential role of <sup>124</sup>I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer
... Abstract: Renal cell carcinoma (RCC) is a biologically heterogeneous disease, with many small renal masses (SRMs) exhibiting an indolent natural history, while others progress more rapidly to ... See full document
13
B7-H3 is a new cancer-specific endothelial marker in clear cell renal cell carcinoma
... mal renal parenchyma specimens from all patients and four corpus luteum specimens were also ...anti-human B7-H3 monoclonal antibody (R&D Systems, Minneapolis, MN, USA), and compared ... See full document
7
B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy
... Targeting B7-H3 over-expressed tumor cells with anti-B7-H3 monoclonal antibodies inhibits tumor ...of B7 family homologue 3 (B7-H3) in a wide range of human tumor ... See full document
12
Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
... T cell infiltrates at baseline, day 8 of cycle 2 (biopsy), and day 2 of cycle 1 (serum) ...phase I open-label study design with four parallel treat- ment arms (1–3 for patients with previously treated mRCC, ... See full document
5
Development of a novel monoclonal antibody to B7-H4: characterization and biological activity
... to target cell lysis or blocking the pathological ...humanized antibody drug plays an important role in clinical therapy of human malignant and other autoimmune diseases ...t cell ... See full document
8
Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy
... : renal cell carcinoma; ccRCC : clear cell renal cell carcinoma; mRCC : metastatic renal cell carcinoma; pRCC : papillary renal cell ... See full document
15
Somatic mutations in renal cell carcinomas from Chinese patients revealed by targeted gene panel sequencing and their associations with prognosis and PD-L1 expression
... T cell activity in the tumor microenvironment, and inhibition of the PD-1/PD-L1 pathway can increase the anti-tumor immune response ...combination therapy or nivolumab monotherapy as a second-line treatment ... See full document
6
5T4 as a target for immunotherapy in renal cell carcinoma
... of antibody is via their transduction to express chimeric immune receptors (CIRs) consisting of a scFv fused to an extracellular spacer domain, coupled to a transmembrane and cytosolic region of a key signaling ... See full document
6
Spectroscopic Photoacoustic Molecular Imaging of Breast Cancer using a B7-H3-targeted ICG Contrast Agent
... concentrated using a molecular weight cutoff centrifugal ...per antibody; however the breadth of the mass spectrometry peak suggests a range in binding ...both B7-H3-ICG and the nonspecific ... See full document
14
The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer
... of B7-H1 or B7-H4 and very weak expression of B7-H3 was found in normal pancreatic tissues (Figure ...of B7-H1, B7-H3, and B7-H4 in pancreatic tissues were ... See full document
8
Identification of clear cell renal cell carcinoma and oncocytoma using a three gene promoter methylation panel
... Nevertheless, over the last years, several high-through- put studies on RCC promoter methylation using an array-based approach, identified several other hyper- methylated genes in RCC, which might be useful as ... See full document
9
Radionuclide I-131 Labeled Albumin-Paclitaxel Nanoparticles for Synergistic Combined Chemo-radioisotope Therapy of Cancer
... It is known that the therapeutic efficacy of energetic β–particles (β–ray) is closely associated with their positions and distribution inside the tumor [38]. However, the dense tumor extracellular matrix structure and ... See full document
10
Experience of Sorafenib as First-Line Treatment in Metastatic Renal Cell Carcinoma in a Tertiary Care Centre
... metastatic renal-cell carcinoma (RCC) with adequate bone marrow, liver, pancreatic, and renal function treated with sorafenib as first-line ... See full document
7
The target therapy of ovarian clear cell carcinoma
... The distinct molecular features of CCC and serous ovar- ian cancer serve to emphasize the need to develop subtype- specific therapeutic approaches in the management of EOC. Patients with CCC have poor prognosis and short ... See full document
6
Upregulation of MIF as a defense mechanism and a biomarker of Alzheimer’s disease
... performed on brain sections from APP23/PS45 mice using a specific anti-MIF antibody. The pattern of MIF staining demonstrated as spotted clusters in both the hippocampal region and cerebral cortex (Fig. ... See full document
12
Related subjects